GABRIELLI, ARMANDO
 Distribuzione geografica
Continente #
NA - Nord America 239
EU - Europa 81
AS - Asia 33
Continente sconosciuto - Info sul continente non disponibili 1
Totale 354
Nazione #
US - Stati Uniti d'America 239
SE - Svezia 38
CN - Cina 27
IT - Italia 15
GB - Regno Unito 9
DE - Germania 8
RU - Federazione Russa 4
FI - Finlandia 3
SG - Singapore 3
ES - Italia 1
EU - Europa 1
FR - Francia 1
IE - Irlanda 1
IR - Iran 1
MD - Moldavia 1
MY - Malesia 1
TR - Turchia 1
Totale 354
Città #
Chandler 49
Nyköping 23
Fairfield 22
Woodbridge 18
Ashburn 16
Ann Arbor 14
Houston 10
Seattle 10
Beijing 9
Cambridge 8
New York 7
Roxbury 7
Wilmington 7
Lawrence 6
Brooklyn 4
Des Moines 4
Bari 3
Dearborn 3
Hefei 3
Jacksonville 3
Monza 3
Boardman 2
Hebei 2
Inglewood 2
Milan 2
Nanjing 2
Princeton 2
San Diego 2
Tianjin 2
Ardabil 1
Augusta 1
Chicago 1
Chisinau 1
Civitanova Marche 1
Dublin 1
Helsinki 1
Indiana 1
Jiaxing 1
Kuala Lumpur 1
Lanzhou 1
Leawood 1
Los Angeles 1
Madrid 1
Monmouth Junction 1
Nanchang 1
Paris 1
Redwood City 1
Rome 1
San Mateo 1
Shenyang 1
Singapore 1
Washington 1
Xian 1
Yiwu 1
Totale 270
Nome #
Validation of the classification criteria for cryoglobulinaemic vasculitis 102
null 63
Early disease and low baseline damage predict response to belimumab in patients with systemic lupus erythematosus 56
Cancrini, Caterina, et al. "Clinical features and follow-up in patients with 22q11. 2 deletion syndrome." The Journal of pediatrics 164.6 (2014): 1475-1480. 46
Risk of acute arterial and venous thromboembolic events in Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss syndrome) 32
Prevalence of peripheral artery disease by abnormal ankle-brachial index in atrial fibrillation: Implications for risk and therapy 28
Efficacy, Safety, and Predictor of Response to Belimumab in a Large Nationwide Cohort Study of Patients with Active Systemic Lupus Erythematosus. 24
null 20
Early administration of tofacitinib in COVID ‐19 pneumonitis: An open randomised controlled trial 4
Early and Late Response and Glucocorticoid-Sparing Effect of Belimumab in Patients with Systemic Lupus Erythematosus with Joint and Skin Manifestations: Results from the Belimumab in Real Life Setting Study—Joint and Skin (BeRLiSS-JS) 3
ACE inhibitors in SSc patients display a risk factor for scleroderma renal crisis - A EUSTAR analysis 2
Totale 380
Categoria #
all - tutte 2.206
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.206


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202059 9 2 2 3 2 4 7 6 3 4 15 2
2020/202155 6 5 1 4 4 5 2 5 1 6 8 8
2021/202266 0 2 2 3 9 11 0 5 3 7 9 15
2022/2023104 15 19 6 7 16 9 3 10 12 1 6 0
2023/202439 0 6 4 5 2 9 1 2 0 1 2 7
2024/20251 1 0 0 0 0 0 0 0 0 0 0 0
Totale 380